TY - JOUR
T1 - Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer
T2 - recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group
AU - Mulder, Renée L
AU - Font-Gonzalez, Anna
AU - van Dulmen-den Broeder, Eline
AU - Quinn, Gwendolyn P
AU - Ginsberg, Jill P
AU - Loeffen, Erik A H
AU - Hudson, Melissa M
AU - Burns, Karen C
AU - van Santen, Hanneke M
AU - Berger, Claire
AU - Diesch, Tamara
AU - Dirksen, Uta
AU - Giwercman, Aleksander
AU - Gracia, Clarisa
AU - Hunter, Sarah E
AU - Kelvin, Joanne F
AU - Klosky, James L
AU - Laven, Joop S E
AU - Lockart, Barbara A
AU - Neggers, Sebastian J C M M
AU - Peate, Michelle
AU - Phillips, Bob
AU - Reed, Damon R
AU - Tinner, Eva Maria E
AU - Byrne, Julianne
AU - Veening, Margreet
AU - van de Berg, Marleen
AU - Verhaak, Chris M
AU - Anazodo, Antoinette
AU - Rodriguez-Wallberg, Kenny
AU - van den Heuvel-Eibrink, Marry M
AU - Asogwa, Ogechukwu A
AU - Brownsdon, Alexandra
AU - Wallace, W Hamish
AU - Green, Daniel M
AU - Skinner, Roderick
AU - Haupt, Riccardo
AU - Kenney, Lisa B
AU - Levine, Jennifer
AU - van de Wetering, Marianne D
AU - Tissing, Wim J E
AU - Paul, Norbert W
AU - Kremer, Leontien C M
AU - Inthorn, Julia
N1 - Funding Information:
This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). We thank Rosalind McDougall (Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia), Adam Glaser (University of Leeds, UK), Zoltan Antal (Memorial Sloan Kettering Cancer Center, New York, NY, USA), Teresa Woodruff (Northwestern University, Chicago, IL, USA), Anja Borgmann-Staudt (Charité Universitätsmedizin, Berlin, Germany), and Joyce Reinecke (Alliance for Fertility Preservation, Lafayette, CA, USA) for critically appraising the recommendations as external reviewers and Eline van der Meulen (Dutch Childhood Cancer Parent Organization/VOX, De Bilt, Netherlands) and Jaap den Hartogh (Dutch Childhood Cancer Parent Organization/VOX, De Bilt, Netherlands) as patient advocates. We also thank the PanCareLIFE Consortium ( appendix p 3 ). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Funding Information:
This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). We thank Rosalind McDougall (Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia), Adam Glaser (University of Leeds, UK), Zoltan Antal (Memorial Sloan Kettering Cancer Center, New York, NY, USA), Teresa Woodruff (Northwestern University, Chicago, IL, USA), Anja Borgmann-Staudt (Charit? Universit?tsmedizin, Berlin, Germany), and Joyce Reinecke (Alliance for Fertility Preservation, Lafayette, CA, USA) for critically appraising the recommendations as external reviewers and Eline van der Meulen (Dutch Childhood Cancer Parent Organization/VOX, De Bilt, Netherlands) and Jaap den Hartogh (Dutch Childhood Cancer Parent Organization/VOX, De Bilt, Netherlands) as patient advocates. We also thank the PanCareLIFE Consortium (appendix p 3). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Funding Information:
JFK was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. MP is supported by a University of Melbourne Medicine, Dentistry and Health Sciences Fellowship. JB received grants from the Boyne Research Institute. AG reports grants from the Swedish Cancer Society and Swedish Childhood Cancer Society, during the conduct of the study; and grants from Ferring Pharmaceuticals and personal fees from Besins Pharamaceuticals, Sandoz, and Finox, outside the submitted work. DRR reports personal fees from LOXO Pharmaceuticals, Shire Pharmaceuticals, Janssen, and Epizyme, outside the submitted work. HMvS received funding from Pfizer and Ferring, outside the submitted work. All other authors declare no competing interests.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/2
Y1 - 2021/2
N2 - Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.
AB - Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.
UR - http://www.scopus.com/inward/record.url?scp=85100094498&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(20)30595-7
DO - 10.1016/S1470-2045(20)30595-7
M3 - Review article
C2 - 33539755
SN - 1470-2045
VL - 22
SP - e68-e80
JO - LANCET ONCOLOGY
JF - LANCET ONCOLOGY
IS - 2
ER -